WINSTON-SALEM, N.C. — Inmar Intelligence, a leading provider of healthcare solutions for hospitals, pharmacies, and life sciences companies, today announced the successful conclusion of an administrative process formalized through a Memorandum of Agreement (MOA) with the U.S. Drug Enforcement Administration (DEA).
The agreement marks the culmination of an 18-month collaborative effort between Inmar and DEA officials to align on the interpretation of regulations surrounding the reverse distribution of controlled substances. While the process was initiated following an Order to Show Cause from the DEA, the Agency acknowledged that there was no diversion of controlled substances from any Inmar facility.
“We are pleased to have concluded this matter with the DEA,” said Brian Nightengale, EVP and President, Healthcare at Inmar Intelligence. “This agreement reflects our dedication to not only meeting but exceeding regulatory requirements. Our continuous improvement measures are designed to set new benchmarks in the industry and ensure the highest standards of security and compliance,” added Nightengale.
Throughout the process, Inmar proactively assessed and upgraded its systems, implementing robust measures designed to enhance compliance and security. These include advanced package-tracking technologies, strengthened security protocols, and expanded employee training initiatives—many of which exceed current regulatory requirements.
In conjunction with the agreement, Inmar has also settled and dismissed its federal lawsuit filed against the U.S. Department of Justice and the DEA in the U.S. District Court for the Northern District of Texas.
